SG11201704934YA - Indenyl compounds, pharmaceutical compositions, and medical uses thereof - Google Patents

Indenyl compounds, pharmaceutical compositions, and medical uses thereof

Info

Publication number: SG11201704934YA
Authority: SG; Singapore
Prior art keywords: pharmaceutical compositions; medical uses; indenyl compounds; indenyl; compounds
Prior art date: 2014-12-16

Adt Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-16Application filed by Adt Pharmaceuticals IncfiledCriticalAdt Pharmaceuticals Inc

2017-07-28Publication of SG11201704934YApublicationCriticalpatent/SG11201704934YA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SG11201704934YA2014-12-162015-12-16Indenyl compounds, pharmaceutical compositions, and medical uses thereofSG11201704934YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14/571,647US9862698B2 (en)	2014-12-16	2014-12-16	Indenyl compounds, pharmaceutical compositions, and medical uses thereof
PCT/US2015/066146WO2016100542A1 (en)	2014-12-16	2015-12-16	Indenyl compounds, pharmaceutical compositions, and medical uses thereof

Publications (1)

Publication Number	Publication Date
SG11201704934YAtrue SG11201704934YA (en)	2017-07-28

Family

ID=55085918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201704934YASG11201704934YA (en)	2014-12-16	2015-12-16	Indenyl compounds, pharmaceutical compositions, and medical uses thereof

Country Status (16)

Country	Link
US (7)	US9862698B2 (en)
EP (2)	EP3233794B1 (en)
JP (3)	JP6698089B2 (en)
KR (1)	KR20170135820A (en)
CN (2)	CN112047909A (en)
AU (1)	AU2015364696B2 (en)
BR (1)	BR112017013012A2 (en)
CA (1)	CA2970803A1 (en)
CL (1)	CL2017001539A1 (en)
CO (1)	CO2017007076A2 (en)
IL (1)	IL252897A0 (en)
MX (2)	MX2021012096A (en)
PH (1)	PH12017501130A1 (en)
RU (1)	RU2017125024A (en)
SG (1)	SG11201704934YA (en)
WO (1)	WO2016100542A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160168108A1 (en)	2014-12-16	2016-06-16	Adt Pharmaceuticals, Inc.	Method of treating or preventing ras-mediated diseases
US9862698B2 (en)	2014-12-16	2018-01-09	Adt Pharmaceuticals, Inc.	Indenyl compounds, pharmaceutical compositions, and medical uses thereof
AU2018209164B2 (en)	2017-01-17	2021-11-04	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3056873A1 (en)*	2017-03-17	2018-09-20	University Of South Alabama	Derivatives of sulindac can protect normal cells against oxidative damage
AU2018323528B2 (en)	2017-08-31	2023-01-12	Leukogene Therapeutics Incorporated	Indene derivatives and uses thereof
US11186596B2 (en)	2018-04-26	2021-11-30	Adt Pharmaceuticals, Llc	Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses
CN113289020B (en)*	2021-05-17	2023-04-18	福州大学	Protein disulfide isomerase small-molecule inhibitor and application thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3325358A (en)*	1962-06-06	1967-06-13	Merck & Co Inc	Method of treating inflammation
NL7005270A (en)	1969-04-29	1970-11-02
US3888902A (en)	1972-10-30	1975-06-10	Merck & Co Inc	Cyano-indenyl acetic acids
US3642785A (en)	1969-08-11	1972-02-15	Merck & Co Inc	Indenyl-3-aliphatic amines
NL7200058A (en)	1971-01-21	1972-07-25
SE7501517L (en)*	1974-02-28	1975-08-29	Merck & Co Inc
EP0132690B1 (en)	1983-07-21	1989-02-01	Troponwerke GmbH & Co. KG	Thermoplastics containing antiphlogistics
US4656190A (en)	1983-11-14	1987-04-07	Merck & Co., Inc.	Indene derivatives and their use as PAF-antagonists
US5093356A (en)	1990-01-16	1992-03-03	Merck Frosst Canada, Inc.	Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
DE69202721T2 (en)	1991-03-08	1995-10-12	Fgn Inc	Substituted indenyl compounds.
US5401774A (en)	1991-03-08	1995-03-28	University Of Arizona	Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
US5965582A (en)	1994-08-03	1999-10-12	Asta Medica Aktiengesellschaft	N-benzylindole and benzopyrazole derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunemodulating effect
US6063818A (en)*	1996-06-13	2000-05-16	Cell Pathways Inc.	Substituted benzylidene indenyl formamides, acetamides and propionamides
US6121321A (en)	1996-06-13	2000-09-19	Cell Pathways, Inc.	Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions
US5965619A (en)	1996-06-13	1999-10-12	Cell Pathways Inc.	Method for treating patients having precancerous lesions with substituted indene derivatives
US6071934A (en)	1997-03-25	2000-06-06	Cell Pathways, Inc.	Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
HUP9903620A3 (en)	1997-06-12	2001-03-28	Univ Arizona Tucson	Pharmaceutical compositions containing substituted benzylidene indenyl formamides, acetamide and propionamide derivatives and use of these compounds
AU752072B2 (en)*	1997-12-12	2002-09-05	Osi Pharmaceuticals, Inc.	N-benzyl-3-indenylacetamides derivatives for treating neoplasia
US6028116A (en)*	1998-04-03	2000-02-22	Cell Pathways, Inc.	Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
US6025394A (en)*	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
AU782971B2 (en)	1999-12-23	2005-09-15	Nicox S.A.	Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US7112638B2 (en)	1999-12-28	2006-09-26	Basell Polyolefine Gmbh	Hetero cyclic metallocene compounds and use thereof in catalyst system for producing olefin polymers
JP2004510762A (en)	2000-10-02	2004-04-08	メルク　エンド　カムパニー　インコーポレーテッド	Inhibitors of prenyl-protein transferase
US20030176316A1 (en)*	2001-08-24	2003-09-18	Whitehead Clark M.	Methods for treatment of rheumatoid arthritis
DE10163426A1 (en)	2001-12-21	2003-07-03	Max Planck Gesellschaft	New 1-(substituted methylene)-1H-indene derivatives, are Ras protein modulators useful for treating tumor or inflammatory diseases
US20030194750A1 (en)	2002-04-05	2003-10-16	Han Li	Methods for treatment of diseases where GSK 3-beta is desired, and methods to identify compounds usefule for that
US6538029B1 (en)	2002-05-29	2003-03-25	Cell Pathways	Methods for treatment of renal cell carcinoma
AU2003279622A1 (en)	2002-06-28	2004-01-19	Nitromed, Inc.	Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
US7491744B2 (en)*	2004-04-26	2009-02-17	Vanderbilt University	Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2006124874A2 (en)	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
EP1960343B1 (en)	2005-11-08	2012-04-04	Laboratorios del Dr. Esteve S.A.	Indene derivatives, their preparation and use as medicaments
GB0525143D0 (en)	2005-12-09	2006-01-18	Novartis Ag	Organic compounds
AU2007205208B2 (en)	2006-01-04	2012-11-01	Southern Research Institute	Derivatives of sulindac, use thereof and preparation thereof
US20090221703A1 (en)	2006-07-09	2009-09-03	Chongxi Yu	High penetration composition and uses thereof
CA2656858C (en)	2006-07-09	2016-01-19	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of acetylsalicylic acid
AU2013206215C9 (en)	2006-07-09	2018-03-08	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of aspirin
AU2016219617B2 (en)	2006-07-09	2018-05-17	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of aspirin
AU2006346288A1 (en)	2006-07-18	2008-01-24	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
AU2013231152B2 (en)	2006-07-18	2016-06-09	Techfields Biochem Co. Ltd	Positively charged water-soluble pro-drugs of ibuprofen
AU2006346759B2 (en)	2006-07-25	2013-07-18	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate
CN101500983B (en)	2006-07-26	2015-09-16	于崇曦	Positively charged water-soluble prodrugs of diflunisal and related compounds with fast skin penetration rate
CN101500984A (en)	2006-07-27	2009-08-05	于崇曦	Positively charged water-soluble prodrugs of ketoprofen and related compounds with rapid skin penetration rate
MX2009001327A (en)	2006-08-07	2009-06-05	Ironwood Pharmaceuticals Inc	Indole compounds.
PT2049482E (en)	2006-08-08	2016-02-24	Techfields Biochem Co Ltd	Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate
EP2054384A4 (en)	2006-08-15	2010-11-03	Techfields Biochem Co Ltd	POSITIVELY-CHARGED WATER-SOLUBLE PRODRUGS CONTAINING ARYL- AND HETEROARYLPROPIONIC ACIDS AND HAVING A VERY HIGH SPEED OF SKIN PENETRATION
AU2013206218B2 (en)	2006-08-15	2016-06-30	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
EP2084132B1 (en)	2006-09-03	2018-08-08	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
AU2014201024B2 (en)	2006-09-03	2016-05-05	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
ES2670407T3 (en)	2006-09-03	2018-05-30	Techfields Biochem Co. Ltd	Positively charged water-soluble acetaminophen prodrugs and compounds related to a very fast skin penetration rate
EP2084165B1 (en)	2006-10-11	2013-06-12	Techfields Biochem Co. Ltd	Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
RU2509076C2 (en)	2007-06-04	2014-03-10	Текфилдз Инк	Prodrugs of nonsteroid anti-inflammatory agents (nsaia) with very high speed of penetration through skin and membranes, and new medical applications of above said prodrugs
SG188957A1 (en)	2010-01-25	2013-05-31	Enanta Pharm Inc	Hepatitis c virus inhibitors
CN103491772A (en)*	2011-04-01	2014-01-01	南方研究所	Derivatives of sulindac, use thereof and preparation thereof
CN105658651A (en)	2012-09-21	2016-06-08	巴兹尔·里格斯	Compositions for the treatment of disorders associated with inflammation, pain and fever, skin disorders, cancer and precancerous conditions thereof
WO2015126462A1 (en)	2014-02-19	2015-08-27	Materia, Inc.	Preparation of surfactants via cross-metathesis
WO2014169080A1 (en)	2013-04-09	2014-10-16	Materia, Inc.	Preparation of surfactants via cross-metathesis
US9862698B2 (en)	2014-12-16	2018-01-09	Adt Pharmaceuticals, Inc.	Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20170342021A1 (en)	2014-12-16	2017-11-30	Adt Pharmaceuticals, Inc.	Ras-inhibiting indenyl acetamide compounds, compositions, and uses
US20160168108A1 (en)	2014-12-16	2016-06-16	Adt Pharmaceuticals, Inc.	Method of treating or preventing ras-mediated diseases
WO2017106520A1 (en)	2015-12-16	2017-06-22	Adt Pharmaceuticals, Inc.	Compounds, compositions and methods of treating cancer
US11186596B2 (en)	2018-04-26	2021-11-30	Adt Pharmaceuticals, Llc	Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses

2014
- 2014-12-16USUS14/571,647patent/US9862698B2/enactiveActive
2015
- 2015-12-16WOPCT/US2015/066146patent/WO2016100542A1/enactiveApplication Filing
- 2015-12-16KRKR1020177019639Apatent/KR20170135820A/ennot_activeWithdrawn
- 2015-12-16RURU2017125024Apatent/RU2017125024A/ennot_activeApplication Discontinuation
- 2015-12-16CNCN202010795274.XApatent/CN112047909A/enactivePending
- 2015-12-16EPEP15823453.4Apatent/EP3233794B1/enactiveActive
- 2015-12-16CACA2970803Apatent/CA2970803A1/enactivePending
- 2015-12-16JPJP2017533501Apatent/JP6698089B2/enactiveActive
- 2015-12-16MXMX2021012096Apatent/MX2021012096A/enunknown
- 2015-12-16BRBR112017013012-2Apatent/BR112017013012A2/ennot_activeApplication Discontinuation
- 2015-12-16SGSG11201704934YApatent/SG11201704934YA/enunknown
- 2015-12-16MXMX2017007840Apatent/MX386761B/enunknown
- 2015-12-16CNCN201580076108.1Apatent/CN107531615B/ennot_activeExpired - Fee Related
- 2015-12-16EPEP22157443.7Apatent/EP4053105A1/enactivePending
- 2015-12-16USUS15/537,292patent/US10526307B2/enactiveActive
- 2015-12-16AUAU2015364696Apatent/AU2015364696B2/ennot_activeCeased
2017
- 2017-06-14CLCL2017001539Apatent/CL2017001539A1/enunknown
- 2017-06-14ILIL252897Apatent/IL252897A0/enunknown
- 2017-06-16PHPH12017501130Apatent/PH12017501130A1/enunknown
- 2017-07-14COCONC2017/0007076Apatent/CO2017007076A2/enunknown
2019
- 2019-10-04USUS16/593,806patent/US10981886B2/enactiveActive
- 2019-10-04USUS16/593,776patent/US10975054B2/enactiveActive
2020
- 2020-02-25JPJP2020029699Apatent/JP2020079307A/ennot_activeWithdrawn
- 2020-03-30USUS16/834,267patent/US11407727B2/enactiveActive
- 2020-03-30USUS16/834,348patent/US11130744B2/enactiveActive
2021
- 2021-09-07JPJP2021145211Apatent/JP2021185193A/ennot_activeWithdrawn
2022
- 2022-06-08USUS17/835,551patent/US20220315553A1/enactivePending

Also Published As

Publication number	Publication date
WO2016100542A1 (en)	2016-06-23
US9862698B2 (en)	2018-01-09
CO2017007076A2 (en)	2018-01-05
CA2970803A1 (en)	2016-06-23
US11407727B2 (en)	2022-08-09
US20200048217A1 (en)	2020-02-13
JP6698089B2 (en)	2020-05-27
CN107531615A (en)	2018-01-02
JP2020079307A (en)	2020-05-28
US20220315553A1 (en)	2022-10-06
JP2021185193A (en)	2021-12-09
KR20170135820A (en)	2017-12-08
AU2015364696B2 (en)	2020-10-15
CN107531615B (en)	2020-09-04
IL252897A0 (en)	2017-08-31
US11130744B2 (en)	2021-09-28
AU2015364696A1 (en)	2017-07-06
EP3233794A1 (en)	2017-10-25
US20160168113A1 (en)	2016-06-16
MX386761B (en)	2025-03-19
US10526307B2 (en)	2020-01-07
EP3233794B1 (en)	2023-02-01
US10975054B2 (en)	2021-04-13
MX2021012096A (en)	2022-10-25
EP4053105A1 (en)	2022-09-07
CL2017001539A1 (en)	2018-03-23
JP2018505145A (en)	2018-02-22
US20180208573A1 (en)	2018-07-26
PH12017501130A1 (en)	2017-11-27
MX2017007840A (en)	2018-03-01
US20200223815A1 (en)	2020-07-16
CN112047909A (en)	2020-12-08
BR112017013012A2 (en)	2018-06-26
US20200031795A1 (en)	2020-01-30
RU2017125024A (en)	2019-01-17
US20200223816A1 (en)	2020-07-16
US10981886B2 (en)	2021-04-20

Publication	Publication Date	Title
IL276695B (en)	2021-09-30	Antibodies, pharmaceutical compositions and uses thereof
EP3102200A4 (en)	2017-07-05	Therapeutic compounds and compositions
IL290114A (en)	2022-03-01	Pharmaceutical composition, preparation and uses thereof
IL252897A0 (en)	2017-08-31	Indenyl compounds, pharmaceutical compositions, and medical uses thereof
HUE056175T2 (en)	2022-01-28	Pharmaceutical compositions, preparation and uses thereof
IL252397A0 (en)	2017-07-31	Pharmaceutical composition, preparation and uses thereof
ZA201703976B (en)	2019-06-26	Dihydropyrimidine-2-one compounds and medicinal uses thereof
IL248773B (en)	2019-12-31	1,6-naphthyridine-4,5-dione derivatives and pharmaceutical compositions comprising them
PT3229843T (en)	2020-03-06	Pharmaceutical composition, preparation and uses thereof
IL252683A0 (en)	2017-08-31	Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
PL3313370T3 (en)	2021-10-25	Ophthalmologic pharmaceutical composition
SG10202106375UA (en)	2021-07-29	Pharmaceutical compositions and use thereof
ZA201500995B (en)	2015-12-23	Low dose pharmaceutical composition
SG11201700122TA (en)	2017-03-30	Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
HK40115817A (en)	2025-04-11	Pharmaceutical composition, preparation and uses thereof

Movatterモバイル変換

SG11201704934YA - Indenyl compounds, pharmaceutical compositions, and medical uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=55085918

Family Applications (1)

Country Status (16)

Families Citing this family (7)

Family Cites Families (61)

Also Published As

Similar Documents